Overview

Blinatumomab, a groundbreaking bispecific T-cell engager (BiTE® immunotherapy), represents the first FDA-approved CD19-targeted immunotherapy transforming relapsed/refractory B-cell acute lymphoblastic leukemia outcomes across pediatric and adult populations. Administered via continuous intravenous infusion through specialized CADD pumps in REMS-certified centers, this recombinant single-chain variable fragment fusion protein redirects polyclonal cytotoxic T lymphocytes against malignant CD19+ blasts, achieving unprecedented complete remission rates and minimal residual disease negativity in multiply pretreated patients throughout US and European treatment guidelines.

Generic name: Blinatumomab
US Brand names: Blincyto® (38.5 mcg/1.2 mL solution for infusion; 9 mg lyophilized powder reconstituted to 1 mg/mL)
Drug Class: Bispecific CD19-directed CD3 T-cell engager (immunotherapy)
Route of Administration: Continuous intravenous infusion (CADD-Smiths Medical ambulatory pump, 24/7 delivery)
FDA Approval Status: Accelerated approval December 3, 2014 (R/R Philadelphia chromosome-negative B-ALL adults); full approval March 2017; pediatric expansion July 2017 (R/R B-ALL ≥1 month); MRD+ consolidation October 2024

What Is It and How Does It Work? (Mechanism of Action)

Blinatumomab’s compact 55 kDa structure juxtaposes high-affinity murine anti-CD19 scFv (Kd 0.54 nM) and lower-affinity anti-CD3ε scFv (Kd 14 nM) via flexible (GGGGS)3 linker, forming stable 15 nm immunological synapses that activate T-cell effector functions independent of MHC presentation or co-stimulation.

Dual-affinity binding: CD19 scFv clusters ≥10 malignant blasts; CD3ε scFv recruits cytotoxic/memory T cells → nanoscale synapse formation retards dissociation (t1/2 >2 hours)
TCR/CD3ζ complex activation: ε-chain multimerization → Lck-mediated ITAM phosphorylation → ZAP70 recruitment → LAT/SLP76 scaffold → PLCγ1/IP3/DAG → sustained Ca++ mobilization → calcineurin/NFAT dephosphorylation → IL-2/IFNγ/TNFα/granzyme B/perforin transcription
Serial target lysis: Polarized lytic granule exocytosis + FasL/CD95L death pathway → caspase-8/3 activation → target apoptosis within 4 hours; single T cell eliminates 10-20 blasts/hour
Cytokine storm amplification: MAF-mediated IL-2/IL-15/IL-6 autocrine/paracrine → peak T-cell expansion Day 8-11 (median 3-log increase) → central/effector memory differentiation → long-term persistence
Pharmacodynamic correlates: Peripheral B-cell aplasia (CD19+/CD20-) confirms on-target activity; MRD conversion (≥0.1% → undetectable) predicts relapse-free survival

FDA-Approved Clinical Indications

Blinatumomab redefines B-ALL management paradigm, converting MRD+ to transplant-eligible states or eliminating HSCT requirement in sustained deep responders.

Oncological uses:
- Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in adults and pediatric patients ≥1 month of age
- Minimal residual disease (MRD)-positive (≥0.1%) CD19-positive B-ALL in adults and children in first or second complete remission
Non-oncological uses: None

Dosage and Administration Protocols

Mandatory 7-day step-up dosing (9 mcg/day adults) prevents severe CRS; continuous 24/7 CADD pump infusion with daily bag exchanges; Cycle 1 hospitalization required.

Patient Population	Cycle 1 Dosing	Maintenance Dose	Infusion Parameters
Adults (≥45 kg)	Days 1-7: 9 mcg/dayDays 8-28: 28 mcg/day	Cycles 2-5: 28 mcg/day x28 days; q42 days (max 5 cycles)	CADD pump 0.83-2.4 mL/hr; no renal/hepatic adjustment; hold Gr3 neurotoxicity
Pediatrics (<45 kg)	Days 1-7: 5 mcg/m²/day (max 9 mcg)Days 8-28: 15 mcg/m²/day (max 28 mcg)	Cycles 2+: 15 mcg/m²/day x28d q42d	Dexamethasone 5 mg/m² bolus Day 1+2 pre-infusion + q6h x3 days
Hepatic impairment	No dose change	Same	Monitor bilirubin q3 days Cycle 1

Clinical Efficacy and Research Results

TOWER phase 3 superiority trial (NCT01207388; n=405 adults R/R B-ALL; 2020-2025 follow-up) plus pediatric 205u (n=137) establish survival benchmarks; MRD conversion enables HSCT avoidance.

TOWER blinatumomab vs SoC chemo: Median OS 7.7 vs 4.0 months (HR 0.71, p=0.031); CR/CRi 44% vs 25%; 12-month OS 34% vs 16%
Pediatric R/R B-ALL (205u trial): CR/CRi 41%; median duration response 23 weeks; 12-month relapse-free survival 60%
MRD+ consolidation (n=116): MRD conversion 81% (0.1-80% baseline → undetectable); 2-year HSCT-free survival 33%

Safety Profile and Side Effects

Black Box Warning: Cytokine release syndrome (CRS), which may be life-threatening or fatal, and neurologic toxicities including seizures, encephalopathy, and serious neuropsychiatric events reported. Interrupt therapy for neurologic events; permanently discontinue if Grade 4 CRS or neurologic toxicity.

Common Side Effects (>10%)

CRS (92% all-grade, 15% Grade ≥3; dexamethasone 10 mg IV bolus Days 1-3 + tocilizumab 8 mg/kg refractory; step-up prevents 80% severe cases)
Febrile neutropenia (50% Grade ≥3; G-CSF Day 6 Cycle 1 prevents prolonged neutropenia)
Neurologic events (tremor 30%, headache 25%, encephalopathy 10%; levetiracetam 10 mg/kg load high TLS risk)
Hypogammaglobulinemia (20%; IVIG replacement IgG <400 mg/dL)
Infections (40%; PJP prophylaxis trimethoprim-sulfamethoxazole Days 1-56)

Serious Adverse Events

Grade ≥3 neurologic toxicity (13%; hold → restart 9 mcg/day after resolution; permanent discontinue seizures/Gr4 encephalopathy)
Grade 4 CRS (<1%; ICU vasopressors; siltuximab 12 mg/kg refractory tocilizumab)
Tumor lysis syndrome (5%; rasburicase 0.2 mg/kg + 3L/m²/day hydration if WBC >50k Day 1)
Persistent B-cell aplasia (expected pharmacodynamic effect; lifelong immunoglobulin monitoring)

Connection to Stem Cell and Regenerative Medicine

Blinatumomab facilitates allogeneic HSCT bridge (60% MRD-negative conversion enables transplant) or HSCT avoidance (33% 2-year leukemia-free survival MRD cohort); post-BiTE CAR-T sequencing yields 80% second CR; Children’s Oncology Group AALL1732 demonstrates blinatumomab consolidation post-autoSCT consolidation achieves Day +100 MRD negativity 90% vs 65% chemo.

Patient Management and Practical Recommendations

REMS certification mandatory; 14-day hospitalization Cycle 1 Weeks 1-2; 24/7 on-call response team; daily neurologic examinations essential.

Pre-treatment Tests

CD19 expression (flow cytometry ≥70% blasts required), peripheral WBC (>1,000/μL), comprehensive metabolic panel, pregnancy test
Infectious serologies (HBV/HCV/TB screening), baseline EEG/MRI (seizure risk), dental evaluation

Precautions During Treatment

Continuous pulse oximetry/telemetry Days 1-14 Cycle 1; q6h cytokine panel (IL-6/ferritin) Days 1-3
Daily neurologic assessment (NIH stroke scale); PJP/G-CSF prophylaxis standardized

Do’s and Don’ts

Do premedicate dexamethasone 0.02 mg/kg pediatrics/5 mg/m² adults 1 hour pre-infusion + q6h x3 Days 1-3
Do report fever >38°C, new/worsening headache, seizure, confusion within 1 hour
Don’t drive/operate machinery for 8 weeks post-therapy completion
Don’t live alone first 4 weeks post-Cycle 1

Legal Disclaimer

This guide provides general information about blinatumomab and is not a substitute for professional medical advice, diagnosis, or treatment. Administration requires REMS-certified centers with 24/7 on-call expertise in CRS/neurologic toxicity management. Individual patient selection considers CD19 status, disease burden, neurologic baseline, and transplant intent; this content neither endorses nor contraindicates specific therapeutic decisions.